Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Puts Faith In Late-Stage Assets In Hopes Of Profit Growth In 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly is making major bets on the oncology and diabetes drugs in its late-stage pipeline in hopes that these assets will fill the hole left by Zyprexa, and soon Cymbalta.

You may also be interested in...



Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution

If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.

Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings

The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.

Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings

The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel